12
COMPARISON OF TWO STRATEGIES FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE IN CROHN'S DISEASE PATIENTS WITH ONE CLINICAL RISK FACTOR: A MULTICENTRE ITALIAN STUDY
Date
May 6, 2023
Explore related products in the following collection:
Tracks
Related Products
IMPEDANCE-PH FINDINGS CONFIRM THAT GRADE B ESOPHAGITIS PROVIDES OBJECTIVE DIAGNOSIS OF GASTROESOPHAGEAL REFLUX DISEASE
Discerning whether laryngeal symptoms are related to reflux (laryngopharyngeal reflux; LPR) is a challenge. Consequently, patients see numerous specialists, undergo multiple diagnostic tests and empirically trial proton pump inhibitors (PPIs), often with inconsistent response…
KONO-S ANASTOMOSIS REDUCES ENDOSCOPIC AND SURGICAL POST-OPERATIVE RECURRENCE IN CROHN’S DISEASE: THE SUPREME-CD TRIAL UPDATE
Aconitate decarboxylase 1 (ACOD1; also known as IRG-1) is the ubiquitous source of the metabolite itaconate, which dampens inflammasome activation by preventing HIF1α production of IL-1β and prevents TNF production through NRF2 activation…
THE ROLE OF HANDHELD ULTRASONOGRAPHY IN PREDICTING DISEASE EXTENSION AND ENDOSCOPIC ACTIVITY IN ULCERATIVE COLITIS
BACKGROUND: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (anti-GM-CSF) have been associated with development of Crohn’s disease (CD) and complications at time of diagnosis. There are limited data on anti-GM-CSF as a prognostic biomarker in CD…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…